Pacific Research Network Inc — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$89,761	2
2023	Research	$332,957	2
2020	Research	$26,199	12
2019	Research	$57,805	22

Breakdown

Who paid Research payments · program years 2019–2024

Vertex Pharmaceuticals Incorporated $407,760 2 payments
Genentech, Inc. $80,490 33 payments
Biogen, Inc. $14,358 1 payment
Takeda Pharmaceuticals U.S.A., Inc. $3,514 1 payment
AbbVie, Inc. $600 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $407,760 2 payments
Gantenerumab Mild Ad $57,203 27 payments
Gantenerumab in Early Ad $23,287 6 payments
A Phase 2, randomized, multicenter, two-arm, open-label study to compare the pharmacodynamics, safety, and tolerability of subcutaneous versus intravenous administration of Aducanumab (BIIB037) in participants with Alzheimer's disease $14,358 1 payment
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD $3,514 1 payment
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimers Disease $600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.